Introduction
============

Lung cancer, the most common type of cancer and the leading cause of cancer-related deaths worldwide, remains a great threat to public health across the world.[@b1-cmar-11-2129] Each year, \>1 million new cases are diagnosed with lung cancer, and over 1 million deaths are attributed to this malignancy.[@b2-cmar-11-2129] As a major type of lung cancer, non-small-cell lung cancer (NSCLC) accounts for \~85% of all lung cancers.[@b3-cmar-11-2129]

Metastasis determines the design of the treatment regimen and prognosis in NSCLC patients.[@b4-cmar-11-2129],[@b5-cmar-11-2129] Brain is a common metastatic site in patients with NSCLC, and \~20%--25% of the NSCLC patients at initial diagnosis are estimated to have brain metastasis.[@b6-cmar-11-2129],[@b7-cmar-11-2129] It has been shown that the NSCLC patients with brain metastases have a poor prognosis, low quality of life, and short survival, with a median survival period of only 1--2 months in untreated patients.[@b8-cmar-11-2129]--[@b11-cmar-11-2129]

Currently, the treatment options for NSCLC with brain metastasis mainly include stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), surgery, chemotherapy, targeted therapy, and symptomatic and supportive treatment.[@b12-cmar-11-2129]--[@b14-cmar-11-2129] WBRT and SRS remain the standard treatment for brain metastases in NSCLC; however, such treatments exhibit limited effects on patients' survival, which only prolong the survival period of 4--6 months.[@b15-cmar-11-2129],[@b16-cmar-11-2129] Conventional therapies, such as chemotherapy, have shown an unsatisfactory efficacy in the treatment of brain metastases in NSCLC due to the presence of blood--brain barrier (BBB).[@b17-cmar-11-2129] A search for treatments that may greatly prolong the survival and improve the prognosis has, therefore, been paid much attention in NSCLC patients with brain metastases.

Driver gene-targeted therapy achieves better survival benefits for the patients with advanced NSCLC, and EGFR is a predominant driver oncogene in NSCLC.[@b18-cmar-11-2129] EGFR-tyrosine kinase inhibitors (TKIs) have been accepted as the initial therapy for advanced NSCLC patients with *EGFR*-sensitive mutations, and EGFR-TKI treatment was reported to achieve an overall response rate (ORR) of 55%--85%, progression-free survival (PFS) of \~12 months, and overall survival (OS) of 24--36 months in advanced *EGFR*-mutant NSCLC patients.[@b19-cmar-11-2129]--[@b21-cmar-11-2129] Data from Phase 3 clinical trials have shown that EGFR-TKI treatment may increase the objective response rate (RR), prolong the PFS, and cause significantly lower incidence of adverse reactions in NSCLC patients relative to in platinum-containing double-drug chemotherapy.[@b22-cmar-11-2129],[@b23-cmar-11-2129]

It has been found that the NSCLC patients harboring an *EGFR* mutation have a higher incidence of brain metastasis (30%--70%) than those without *EGFR* mutations, and the management of brain metastasis is, therefore, critical to antitumor therapy in NSCLC patients harboring an *EGFR* mutation.[@b24-cmar-11-2129]--[@b27-cmar-11-2129] Data from clinical trials have demonstrated that EGFR-TKIs may cause regression of established brain metastases from NSCLC, with an intracranial RR of 75% in treatment-naïve, advanced *EGFR*-mutant NSCLC patients.[@b28-cmar-11-2129]--[@b30-cmar-11-2129] To date, the optimal timing of brain radiotherapy, however, remains controversial in *EGFR*-mutant lung cancer patients with brain metastasis in the presence of well-controlled intracranial and extracranial lesions by EGFR-TKIs. The present study was, therefore, designed to compare the efficacy of concurrent EGFR-TKIs and WBRT vs EGFR-TKI alone in a retrospective cohort of advanced *EGFR*-mutant NSCLS with brain metastases, so as to provide insights into the optimal timing of brain radiotherapy.

Patients and methods
====================

Study subjects
--------------

The medical records of 104 treatment-naïve, advanced *EGFR*-mutant NSCLC patients with brain metastases admitted to Fujian Provincial Cancer Hospital (Fuzhou, People's Republic of China) during the period from January 1, 2012 to June 30, 2017 were retrospectively reviewed. All NSCLCs were definitively diagnosed with pathologic examinations, and *EGFR* mutation analysis was performed using amplification refractory mutation system PCR or next-generation sequencing. There were 56 patients undergoing concurrent EGFR-TKI and WBRT, and 48 patients given EGFR-TKI alone, including 20 cases with salvage WBRT upon brain metastasis progression.

Treatment regimens
------------------

All patients received an initial MRI scan of the brain prior to administration of EGFR-TKIs and every 2--3 months post-treatment with EGFR-TKIs. All subjects were given 150 mg erlotinib (Roche, Basel, Switzerland) once a day (QD), 250 mg gefitinib (AstraZeneca Pharmaceuticals, Waltham, MA, USA) QD or 150 mg icotinib (Betta Pharmaceuticals Co., Ltd., Hangzhou, People's Republic of China) three times a day, and WBRT was delivered at a dose of 30 Gy divided in ten fractions for 5 days a week, given at a total of 2 weeks. The response to therapy was evaluated according to the Response Evaluation Criteria in Solid Tumor version 1.1, 1 month after the initial treatment with EGFR-TKIs,[@b31-cmar-11-2129] followed by once every 2--3 months, and the adverse events were assessed according to the Common Terminology Criteria for Adverse Events version 4.0.[@b32-cmar-11-2129]

Survival analysis
-----------------

Intracranial PFS (iPFS) was defined as the survival from initial EGFR-TKIs treatment to intracranial progression following WBRT. OS was estimated from the date of initial diagnosis until the date of death or the last follow-up.

Statistical analysis
--------------------

All data were entered into Microsoft Excel 2007 (Microsoft, Inc., Redmond, WA, USA), and all statistical analyses were performed using the statistical software SPSS version 23.0 (IBM Corporation, Armonk, NY, USA). Chi-squared test or Fisher's exact test was used to compare the clinicopathologic characteristics between the two cohorts. Survival curves were generated using the Kaplan--Meier method, and the survival probability was compared with the log-rank test. A Cox regression model was employed for univariate and multivariate analyses to evaluate the corresponding 95% CIs and HRs. A *P* value of \<0.05 was considered statistically significant.

Informed consent
----------------

All participants signed the informed consent pertaining to targeted therapy or brain radiotherapy. All subjects involved in this study agreed to publish related demographic and clinical features.

Ethical approval
----------------

The study protocol was reviewed and approved by the Ethical Review Committee of Fujian Provincial Cancer Hospital (approval no. FJZLYY2015-00179). All experimentations described in this study were conducted in accordance with the Declaration of Helsinki.

Results
=======

Clinicopathologic characteristics of the study subjects
-------------------------------------------------------

The study subjects included 45 men and 59 women, and had a median age of 59 years (range, 23--79 years) at diagnosis. Of all subjects, 97.1% were diagnosed with adenocarcinoma and 88.5% had an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. There were 83 cases with extracranial metastases and 48 cases with symptomatic brain metastases initially. In addition, there were 39 cases harboring an *EGFR* exon 19 deletion mutation, 39 cases harboring an *EGFR* exon 21L858R mutation, 5 cases harboring an *EGFR* exon 21L861Q mutation, 4 cases harboring an *EGFR* exon 18G719X mutation, 4 cases harboring combined *EGFR* exon 21L858R and exon 20 T790M mutations, 4 cases harboring combined *EGFR* exon 19 deletion mutation and exon 20 T790M mutation, while the mutation sites of the other 9 cases were unclear. The baseline clinicopathologic features were balanced between the two cohorts ([Table 1](#t1-cmar-11-2129){ref-type="table"}).

Intracranial progression
------------------------

The subjects received follow-up for a median period of 23 months (range, 5--82 months). At the end of the follow-up period (June 30, 2017), 36 subjects remained alive and 66 cases were dead due to disease progression. Of all subjects, 86 cases (82.7%) had an intracranial progressive disease, with a median iPFS of 14.5 months (95% CI, 11.924--17.076 months). Intracranial progression developed in 76.8% (43/56) of the patients receiving EGFR-TKIs plus and WBRT, while intracranial progression occurred in 89.6% (43/48) of the cases given EGFR-TKIs alone. The median iPFS was 17.7 months (95% CI, 16.288--22.212 months) in the patients receiving concurrent EGFR-TKIs and WBRT, which was significantly longer than that of those given EGFR-TKIs alone (median iPFS, 11.0 months; 95% CI, 8.067--13.933 months; *P*=0.015), as shown in [Table 2](#t2-cmar-11-2129){ref-type="table"} and [Figure 1](#f1-cmar-11-2129){ref-type="fig"}.

The 70 patients with more than three brain metastases had a median iPFS of 12.5 months (95% CI, 12.952--17.432 months), which was significantly shorter than that of 34 cases with three or less brain metastases (median iPFS, 18.0 months; 95% CI, 16.142--23.554 months; *P*=0.044), as shown in [Figure 2](#f2-cmar-11-2129){ref-type="fig"}.

Among the study subjects, there were 6 patients (5.8%) with complete response and 42 patients (40.4%) with partial response, yielding an ORR of 46.2%. In addition, there were 52 patients (50.0%) with stable disease. The ORR was comparable between the patients receiving concurrent EGFR-TKIs and WBRT and EGFR-TKIs alone (48.2% vs 54.2%, *P*=0.562; [Table 3](#t3-cmar-11-2129){ref-type="table"}). Cox multivariate regression analysis revealed that concurrent EGFR-TKIs and WBRT was an independent predictor of iPFS (*P*=0.004) and more than three brain metastases was a potential independent predictor unfavorably affecting iPFS in advanced *EGFR*-mutant NSCLC patients (*P*=0.017; [Table 4](#t4-cmar-11-2129){ref-type="table"}).

Survival outcomes
-----------------

Thirty-six patients survived until the end of the followup period. Among all study subjects, the median OS was 27.3 months (95% CI, 23.109--31.491 months), and no significant difference was found in the median OS between the patients receiving concurrent EGFR-TKIs and WBRT (median OS, 28.1 months; 95% CI, 23.975--32.225 months) and EGFR-TKIs alone (median OS, 24.0 months; 95% CI, 17.428--30.572 months), with a *P*-value of 0.756. Among the 48 patients given EGFR-TKIs alone, there were 20 cases with salvage WBRT upon brain metastasis progression, and the median OS did not significantly differ in patients receiving concurrent EGFR-TKIs and WBRT (median OS, 28.1 months; 95% CI, 23.975--32.225 months), salvage WBRT (median OS, 36.1 months; 95% CI, 19.678--52.622 months), and EGFR-TKIs alone (median OS, 22.5 months; 95% CI, 14.990--30.010 months), with a *P*-value of 0.366 ([Figure 3](#f3-cmar-11-2129){ref-type="fig"}).

Subgroup analyses
-----------------

Subgroup analyses revealed that of the 70 patients with more than three brain metastases, the median iPFS was significantly longer in cases receiving concurrent EGFR-TKIs and WBRT (median iPFS, 17.6 months; 95% CI, 14.176--21.024 months) than in those given EGFR-TKIs alone (median iPFS, 9.2 months; 95% CI, 6.924--11.476 months; *P*=0.001), as shown in [Figure 4](#f4-cmar-11-2129){ref-type="fig"}. Among the 34 patients with three or less brain metastases, however, no significant difference was detected in the median iPFS between the patients receiving concurrent EGFR-TKIs and WBRT and EGFR-TKIs alone (*P*=0.526; [Figure 5](#f5-cmar-11-2129){ref-type="fig"}).

Toxicity
--------

During the treatment period, the incidence of adverse events was 85.7% and 83.3% in the subjects receiving concurrent EGFR-TKIs and WBRT and EGFR-TKIs alone. In cases given EGFR-TKIs alone, the incidence of grade 3 and higher adverse events was 2.1%, and in the cases receiving concurrent EGFR-TKIs and WBRT, the incidence of grade 3 and higher adverse events was 8.9%, including a case with reduced drug doses due to the development of grade 3 diarrhea. The WBRT-related adverse events mainly included dizziness and headache, which were alleviated following dehydration treatment, as well as neurocognitive impairment (grade 1 and 2 in three cases and grade 3 in one case), as shown in [Table 5](#t5-cmar-11-2129){ref-type="table"}.

Discussion
==========

Currently, the treatment of advanced NSCLC with brain metastasis remains a great challenge,[@b8-cmar-11-2129]--[@b10-cmar-11-2129] and *EGFR*-mutant NSCLC has been found to be more likely to present brain metastases.[@b24-cmar-11-2129]--[@b27-cmar-11-2129] Prior to the introduction of EGFR-TKI, WBRT, surgical resection of the metastatic lesions, and SRS were the standard treatments of brain metastasis; however, radiotherapy and surgery cause non-ignorable brain damages, which may seriously affect patients' survival and quality of life.[@b12-cmar-11-2129]--[@b16-cmar-11-2129] EGFR-TKI is an emerging effective treatment option for EGFR-mutant lung cancer patients with brain metastasis.[@b33-cmar-11-2129] Results from the CTONG-0803 Phase 2 clinical trial showed that the single-agent erlotinib at a daily dose of 150 mg was active and well tolerated as a second-line therapy in NSCLC patients with brain metastasis, which achieved 10.1 months iPFS.[@b34-cmar-11-2129] Another multicenter, Phase 3, open-label, parallel, randomized controlled trial to compare the efficacy of icotinib vs whole-brain irradiation with or without chemotherapy revealed that icotinib treatment (median iPFS, 10.1 months) achieved significantly longer iPFS than WBI plus chemotherapy (median iPFS, 4.8 months) in patients with *EGFR*-mutant NSCLC and multiple brain metastases.[@b35-cmar-11-2129] Since brain radiotherapy may cause brain injuries, the optimal timing of brain radiotherapy remains in dispute until now. In *EGFR*-mutant NSCLC patients with brain metastasis, is the first-line brain radiotherapy is required? Does brain radiotherapy serve as a salvage therapy upon intracranial tumor progression? These questions remain to be answered. Previous studies have shown that concurrent EGFR-TKI and brain radiotherapy (WBRT or SRS) may increase the intracra-nial disease control rate and extend the OS in *EGFR*-mutant NSCLC patients.[@b36-cmar-11-2129]--[@b38-cmar-11-2129] In addition, a recent multi-institutional analysis demonstrated that SRS followed by EGFR-TKI resulted in the longest OS and allowed patients to avoid the potential neurocognitive sequelae of WBRT in *EGFR*-mutant NSCLC patients with brain metastases.[@b39-cmar-11-2129]

Our data showed that concurrent EGFR-TKIs and WBRT achieved significantly longer iPFS than EGFR-TKIs alone (median iPFS, 17.7 vs 11.0 months, *P*=0.015), which was similar to a previous study reporting that concurrent early brain radiotherapy with EGFR-TKI may improve intracranial disease control in *EGFR*-mutant NSCLC with brain metastasis.[@b38-cmar-11-2129] Results from a Phase 2 clinical trial showed that erlotinib in combination with WBRT was well tolerated with a favorable objective RR in patients with brain metastases from NSCLC.[@b40-cmar-11-2129] Due to the protection of the BBB, the drug concentration is not high in the central nervous system (CNS).[@b41-cmar-11-2129] Therefore, optimal CNS penetration is a critical issue for patients with brain metastases.[@b42-cmar-11-2129] Brain radiotherapy is found to destroy the BBB and increase the TKIs concentration in the cerebrospinal fluid.[@b43-cmar-11-2129],[@b44-cmar-11-2129] In addition, it has been shown that *EGFR* mutation is a radiosensitive NSCLC genotype and EGFR-TKI is supposed to be a radiosensitizer.[@b43-cmar-11-2129],[@b45-cmar-11-2129],[@b46-cmar-11-2129] It is, therefore, hypothesized that EGFR-TKI and WBRT may have a synergistic effect, and the combination of EGFR-TKI and WBRT may result in better intracranial tumor control in NSCLC harboring *EGFR* mutations. Taking these findings together, it is considered that concurrent EGFR-TKIs with WBRT may achieve better intracranial tumor control in NSCLC harboring *EGFR* mutations.

In the current study, concurrent EGFR-TKIs with WBRT (median OS, 28.1 months) achieved extension of the OS relative to EGFR-TKIs alone (median OS, 24 months), although no significant difference was seen between these two regimens in terms of the median OS (*P*=0.756). Of the 48 patients initially treated with EGFR-TKI alone, there were 20 cases receiving salvage WBRT upon brain metastasis progression, and 58.3% of the cases lost the timing for WBRT due to physical intolerance and treatment abandonment. Our data showed no significant difference in the OS between the patients receiving concurrent EGFR-TKIs with WBRT and EGFR-TKIs alone. Follow-up revealed that the majority of the patients were well tolerant to WBRT, with only a case developing grade 3 neurocognitive impairment, who had a 4.5 OS. Further studies to examine the effect of WBRT-induced neurocognitive impairment on survival in *EGFR*-mutant NSCLC patients with brain metastasis are required. We, therefore, recommend concurrent EGFR-TKI with brain radiotherapy as an initial therapy for *EGFR*-mutant NSCLC patients with brain metastasis. A retrospective multi-institutional analysis showed that SRS followed by EGFR-TKI (46 months) achieved longer median OS than WBRT followed by EGFR-TKI (30 months) and EGFR-TKI followed by SRS or WBRT (25 months) at intracranial progression in *EGFR*-mutant NSCLC patients with brain metastases (*P*\<0.001).[@b39-cmar-11-2129] In addition, SRS was found to have less toxicity and avoided the potential neurocognitive sequelae from WBRT.[@b47-cmar-11-2129],[@b48-cmar-11-2129] EGFR-TKI plus brain radiotherapy, notably SRS, as an initial therapy, may improve the survival and avoid losing the timing for radiotherapy, which may be an optimal option for the treatment of *EGFR*-mutant NSCLC with brain metastasis. However, a prospective, randomized clinical trial is urgently needed to confirm the findings.

In this study, a Cox multivariate regression analysis revealed that the number of brain metastasis was an independent predictor of iPFS, and advanced EGFR-mutant NSCLC patients with three or less brain metastases at initial diagnosis affected iPFS favorably. Previous studies have demonstrated that ECOG performance status, EGFR mutation subtype, and absence of extracranial metastases are independent predictors of iPFS and OS in NSCLC patients with brain metastasis,[@b39-cmar-11-2129],[@b49-cmar-11-2129] which was not found in the present study. Our data report a single-institution experience and the study sample is small. Further large-scale, multicenter, retrospective studies to identify the factors affecting iPFS and OS in NSCLC patients with brain metastasis are warranted.

Currently, neurosurgery or radiosurgery is the standard option for the radical therapy of locally intracranial metastatic tumors, and SRS is accepted as the first choice for the local treatment of locally intracranial metastatic tumors.[@b50-cmar-11-2129],[@b51-cmar-11-2129] However, either surgery or radiotherapy is invasive and has side effects, while EGFR-TKI shows a high response and few adverse effects for intracranial metastatic tumors.[@b50-cmar-11-2129],[@b51-cmar-11-2129] To defer or avoid neurocognitive sequelae from WBRT, it is necessary to identify the patient population given EGFR-TKI alone as the initial therapy. Our subgroup analysis showed that concurrent EGFR-TKI and WBRT improved median iPFS compared with EGFR-TKI alone in patients with more than three brain metastases (*P*=0.001); however, no significant difference was observed between the two regimens in patients with three or less brain metastases (*P*=0.526). It is hypothesized that, in *EGFR*-mutant NSCLC with three or less brain metastases, EGFR-TKI alone may be an option as a first-line therapy; however, this requires further investigations to test such a hypothesis. Osimertinib, an oral, CNS-active, third-generation EGFR-TKI, was found to be effective in crossing the BBB and penetrating the CNS.[@b52-cmar-11-2129] Data from the FLAURA study revealed that osimertinib achieved a significantly higher CNS objective RR (66%) than the first-generation EGFR-TKI and remarkably reduced the risk of intracranial progression in advanced NSCLC patients with EGFR-TKI-sensitizing mutation.[@b53-cmar-11-2129] In Asian patients with previously untreated advanced NSCLC harboring exon 19 deletion (Ex19del)/L858R EGFR-TKI-sensitizing mutations, first-line osimertinib demonstrated a clinically meaningful improvement in PFS over the standard of care EGFR-TKI (gefitinib or erlotinib) (median PFS, 16.5 vs 11.0 months, HR =0.54, 95% CI, 0.41--0.72; *P*\<0.0001).[@b54-cmar-11-2129] However, more investigations are required to demonstrate the likelihood of osimertinib as an alternative of brain radiotherapy in EGFR-mutant, advanced NSCLC patients with brain metastases. In addition, prospective studies are needed to identify the patient population given EGFR-TKI alone in whom brain radiotherapy is not needed, in order to protect them against radiation-induced neurocognitive sequelae from WBRT.

Conclusion
==========

The results of the present study demonstrate that concurrent EGFR-TKI and WBRT may improve intracranial disease control in advanced *EGFR*-mutant NSCLC with brain metastasis. Initial treatment with EGFR-TKI alone may cause a loss of timing for WBRT, and concurrent EGFR-TKI with WBRT may be an optimal option for *EGFR*-mutant NSCLC with brain metastasis at the initial diagnosis. However, EGFR-TKI alone may be an option as the first-line therapy in patients with three or less brain metastases, which may defer or avoid neurocognitive sequelae from WBRT. Further multi-institutional, prospective, randomized clinical trials to validate our findings and determine the optimal treatment for *EGFR*-mutant NSCLC with brain metastasis seem justified.
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![Kaplan--Meier curves for iPFS in advanced *EGFR*-mutant NSCLC patients.\
**Notes:** The median iPFS is significantly longer in patients receiving concurrent EGFR-TKIs and WBRT than in those given EGFR-TKIs alone (17.7 vs 11.0 months, *P*=0.015).\
**Abbreviations:** iPFS, intracranial progression-free survival; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.](cmar-11-2129Fig1){#f1-cmar-11-2129}

![Kaplan--Meier curves for iPFS in advanced *EGFR*-mutant NSCLC patients with various number of brain metastases.\
**Note:** Patients with more than three brain metastases had significantly shorter median iPFS than those with three or less brain metastases (12.5 vs 18.0 months, *P*=0.044).\
**Abbreviations:** iPFS, intracranial progression-free survival; NSCLC, non-small-cell lung cancer.](cmar-11-2129Fig2){#f2-cmar-11-2129}

![Kaplan--Meier curves for OS in advanced *EGFR*-mutant NSCLC patients receiving various treatment regimens.\
**Note:** The median OS did not significantly differ in patients receiving concurrent EGFR-TKIs and WBRT (median OS, 28.1 months; 95% CI, 23.975--32.225 months) and EGFR-TKIs alone (median OS, 24.0 months; 95% CI, 17.428--30.572 months), with the *P*-value being 0.756.\
**Abbreviations:** NSCLC, non-small-cell lung cancer; OS, overall survival; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.](cmar-11-2129Fig3){#f3-cmar-11-2129}

![Subgroup analysis of iPFS in advanced *EGFR*-mutant NSCLC patients with more than three brain metastases.\
**Note:** The median iPFS was significantly longer in patients receiving concurrent EGFR-TKIs and WBRT than in those given EGFR-TKIs alone (17.6 vs 9.2 months, *P*=0.001).\
**Abbreviations:** iPFS, intracranial progression-free survival; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.](cmar-11-2129Fig4){#f4-cmar-11-2129}

![Subgroup analysis of iPFS in advanced *EGFR*-mutant NSCLC patients with three or less brain metastases.\
**Note:** The median iPFS was comparable between the patients receiving concurrent EGFR-TKIs and WBRT and EGFR-TKIs alone (19.2 vs 14.5 months, *P*=0.526).\
**Abbreviations:** iPFS, intracranial progression-free survival; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.](cmar-11-2129Fig5){#f5-cmar-11-2129}

###### 

Clinicopathologic characteristics of the study subjects

  Characteristics                     Total subjects (N=104)   EGFR-TKI plus WBRT (n=56)   EGFR-TKI (n=48)   *P*-value          
  ----------------------------------- ------------------------ --------------------------- ----------------- ----------- ------ -------
                                                                                                                                
  Gender                                                                                                                        
   Male                               45                       25                          55.6              20          44.4   0.843
   Female                             59                       31                          52.5              28          47.5   
  Age (years)                                                                                                                   
   \>60                               37                       19                          51.2              18          48.6   0.837
   ≤60                                67                       37                                            30                 
  ECOG-PS score                                                                                                                 
   0--1                               92                       48                          52.2              44          47.8   0.377
   ≥2                                 12                       8                           66.7              4           33.3   
  Symptomatic brain metastasis                                                                                                  
   Yes                                48                       29                          60.4              19          39.6   0.241
   No                                 56                       27                          48.2              29          51.8   
  Smoking status                                                                                                                
   Never                              77                       41                          53.2              36          46.8   0.836
   Former                             27                       15                          55.6              12          44.4   
  *EGFR* mutations                                                                                                              
   19 del                             39                       18                          46.2              21          53.8   0.173
   L858R                              39                       20                          51.3              19          48.7   
   Others                             26                       18                          69.2              8           30.8   
  Extracranial metastasis initially                                                                                             
   Yes                                83                       45                          54.2              38          45.8   0.880
   No                                 21                       11                          52.3              10          47.6   
  Number of brain metastases, n                                                                                                 
   \>3                                70                       30                          42.9              40          57.1   0.403
   ≤3                                 34                       16                          47.1              18          52.9   
  Histology                                                                                                                     
   Adenocarcinoma                     101                      56                          55.4              45          44.6   0.095
   Others                             3                        0                           0                 3           100    

**Abbreviations:** ECOG-PS, Eastern Cooperative Oncology Group Performance Status; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.

###### 

iPFS and OS according to subgroups

                                      n    Median iPFS (months)   95% CI           *P*-value   Median OS (months)   95% CI           *P*-value
  ----------------------------------- ---- ---------------------- ---------------- ----------- -------------------- ---------------- -----------
                                                                                                                                     
  Gender                                                                                                                             
   Male                               45   14.2                   9.362--19.038    0.584       25.5                 17.718--33.282   0.380
   Female                             59   15.1                   13.683--16.517               28.0                 21.150--34.850   
  Age (years)                                                                                                                        
   \>60                               37   17.6                   11.421--16.579   0.649       28.3                 21.815--34.785   0.326
   ≤60                                67   14.0                   13.037--22.163               25.5                 29.575--31.425   
  ECOG-PS                                                                                                                            
   0--1                               92   14.5                   11.291--17.709   0.952       25.4                 20.760--30.040   0.198
   ≥2                                 12   14.5                   4.316--24.684                25.5                 2.705--48.295    
  Symptomatic of BM                                                                                                                  
   Yes                                36   17.6                   13.787--21.413   0.218       28.0                 24.122--31.878   0.953
   No                                 68   14.0                   10.780--17.220               25.4                 19.988--30.812   
  Smoking status                                                                                                                     
   Never                              77   14.5                   11.882--17.118   0.996       27.3                 22.842--31.758   0.761
   Former                             27   16.1                   9.124--23.076                25.5                 16.953--34.047   
  EGFR mutations                                                                                                                     
   19 del                             39   14.5                   11.634--16.214   0.915       27.5                 17.050--38.365   0.356
   L858R                              39   15.1                   13.852--16.786               22.1                 17.552--26.865   
   Other                              26   17.2                   12.466--21.756               28.2                 23.678--32.986   
  Extracranial metastasis initially                                                                                                  
   Yes                                83   14.5                   11.031--17.969   0.362       24.0                 18.579--29.421   0.203
   No                                 21   15.1                   6.179--24.021                28.4                 24.543--32.257   
  Number of BMs                                                                                                                      
   \>3                                70   12.5                   12.952--17.432   0.044       27.3                 21.633--32.967   0.696
   ≤3                                 34   18.0                   16.142--23.554               30.0                 21.027--38.973   
  Therapy method                                                                                                                     
   EGFR-TKI plus WBRT                 56   17.7                   16.288--22.212   0.015       28.1                 23.975--32.225   0.756
   EGFR-TKI alone                     48   11.0                   8.067--13.933                24.0                 17.428--30.572   

**Abbreviations:** ECOG-PS, Eastern Cooperative Oncology Group Performance Status; iPFS, intracranial progression-free survival; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.

###### 

Response to therapy in the two study cohorts

  Response   EGFR-TKI plus WBRT (n=48)   EGFR-TKI alone (n=56)   Total n (%)
  ---------- --------------------------- ----------------------- -------------
                                                                 
  CR         2                           4                       6 (5.8%)
  PR         25                          22                      47 (45.2%)
  SD         25                          20                      45 (43.2%)
  PD         2                           2                       4 (3.8%)
  ORR        48.2%                       54.2%                   104 (100%)

**Abbreviations:** CR, complete response; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.

###### 

Univariable and multivariable analyses of covariables associated with intracranial progression-free survival

  Characteristics              n    Univariate             Multivariate                          
  ---------------------------- ---- ---------------------- -------------- ---------------------- -------
                                                                                                 
  Number of brain metastasis                                                                     
   \>3                         70   1.533 (0.969--2.427)   0.068          1.785 (1.110--2.871)   0.017
   ≤3                          34                                                                
  Therapy method                                                                                 
   EGFR-TKI + WBRT             56   0.590 (0.385--0.903)   0.015          0.504 (0.336--0.807)   0.004
   EGFR-TKI                    48                                                                

**Abbreviations:** TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.

###### 

Treatment-related toxicities

                         EGFR-TKI concurrent WBRT (n=56)   EGFR-TKI alone (n=48)                   
  ---------------------- --------------------------------- ----------------------- --------------- ----------
                                                                                                   
  Total adverse events   48/56 (85.7%)                                             40/48 (83.3%)   
  Elevated ALT/AST       15 (26.8%)                        1 (1.8%)                11 (22.9%)      0
  Elevated bilirubin     6 (10.7%)                         0                       5 (10.4%)       0
  Rash                   15 (26.8%)                        2 (3.6%)                17 (35.4%)      1 (2.1%)
  Fatigue                8 (14.3%)                         0                       10 (20.8%)      0
  Nausea                 7 (12.5%)                         0                       5 (10.4%)       0
  Vomiting               4 (7.1%)                          0                       3 (6.3%)        0
  Diarrhea               3 (5.4%)                          1 (1.8%)                5 (10.4%)       0
  Dizziness              15 (26.8%)                        0                       0               0
  Headache               11 (19.6)                         0                       0               0
  Cognitive disorder     3 (5.4%)                          1 (1.8%)                0               0

**Abbreviations:** TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.

[^1]: These authors contributed equally to this work
